Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Novartis Ag (NVSEF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Novartis Ag (NVSEF) over the last 17 years, with Q4 2025 value amounting to 436.71%.

  • Novartis Ag's EBITDA Margin rose 4098800.0% to 436.71% in Q4 2025 from the same period last year, while for Dec 2025 it was 536.94%, marking a year-over-year increase of 5080400.0%. This contributed to the annual value of 32.36% for FY2025, which is 34500.0% up from last year.
  • Novartis Ag's EBITDA Margin amounted to 436.71% in Q4 2025, which was up 4098800.0% from 616.58% recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's EBITDA Margin registered a high of 709.74% during Q1 2025, and its lowest value of 14.96% during Q3 2023.
  • Its 5-year average for EBITDA Margin is 129.36%, with a median of 24.68% in 2021.
  • Per our database at Business Quant, Novartis Ag's EBITDA Margin plummeted by -94200bps in 2022 and then skyrocketed by 6812300bps in 2025.
  • Over the past 5 years, Novartis Ag's EBITDA Margin (Quarter) stood at 19.37% in 2021, then decreased by -14bps to 16.59% in 2022, then surged by 36bps to 22.6% in 2023, then rose by 19bps to 26.84% in 2024, then soared by 1527bps to 436.71% in 2025.
  • Its EBITDA Margin was 436.71% in Q4 2025, compared to 616.58% in Q3 2025 and 454.15% in Q2 2025.